Autoimmune diseases (AID) sometimes coexist with hematological malignancies, and allogeneic hematopoietic SCT (HSCT) may be performed in patients with hematological neoplasms and AID. 1, 2 Snowden et al. 3 reported 1209 autologous and 64 allogeneic HSCTs in AID patients from the European Group for Blood and Marrow Transplantation database, and only 4 cases of allogeneic HSCT in patients with vasculitis were listed. Takayasu arteritis (TA) is characterized by large-vessel arteritis affecting the aorta and its primary branches, and it shows strong predominance in women. Oral prednisolone (PSL) is standard therapy, and second-line treatments-CY, MTX and CsA-are used for steroid-refractory patients. Several reports indicated an association between myelodysplastic syndrome (MDS) and TA. [4] [5] [6] [7] We report a case of MDS and TA in which carotid artery stenosis was significantly improved after cord blood transplantation (CBT).
The patient had a medical history of non-Hodgkin lymphoma at 10 years of age, was treated with chemotherapy (vincristine, CY, MTX and PSL) and involved-field radiotherapy (20 Gy) to the anterior mediastinum, and achieved CR. At age 28, she developed pancytopenia (neutrophils 988/mL, Hb 7.9 g/dL, platelets 4.5 Â 10 4 / mL and reticulocytes 3.4 Â 10 4 /mL), and was diagnosed with moderate aplastic anemia. Computed tomography (CT) detected left carotid artery stenosis. Despite immunosuppressive therapy, including anti-thymocyte globulin, PSL (7.5 mg/day) and CsA (100 mg/day), hematological findings gradually worsened (neutrophils 603/mL, Hb 8.1 g/dL, reticulocytes 2.0 Â 10 4 /mL and platelets 1.1 Â 10 4 /mL) and regular transfusions were required from age 30. At age 33, BM smear showed erythroid cell dysplasia and trisomy 8. A diagnosis of MDS was made and she was referred to our department for HSCT. Since the chemotherapy for lymphoma was given at the age of 10 years, she appeared to have therapy-related MDS. Contrast-enhanced CT and magnetic resonance imaging (MRI) before transplantation showed left common carotid arterial wall thickening (Figures 1a and c), which remained unchanged since before immunosuppressive therapy for aplastic anemia. Bruit over the neck was detected. Screening tests for AID, including anti-nuclear Ab and anti-neutrophil cytoplasmic Abs, were negative and there were no signs of infection that could be associated with other forms of vasculitis. Then, a diagnosis of TA was made. CBT was performed because no related or unrelated donor was available. The conditioning regimen consisted of fludarabine (30 mg/m 2 for 5 days), CY (60 mg/kg for 2 days) and low-dose TBI (4 Gy). Tacrolimus and short-term MTX (10 mg/m 2 on day 1, 7 mg/m 2 on days 3 and 6) were used as prophylaxis for GVHD. No HLA-linked susceptibility gene of TA was detected in donor or recipient HLA typing. Neutrophil engraftment was achieved on day 17, and 100% donor type chimerism was confirmed by the STR method. She had acute skin GVHD, which was resolved with topical steroid application. She was discharged on day 44 and no chronic GVHD or other complications occurred during follow-up. Tacrolimus was tapered off 10 months after CBT. MRI and CT were performed 2 and 3 years after CBT, respectively, and atrial wall thickening of the left common carotid artery disappeared completely (Figures 1b and d) . MRI showed that the mean internal diameter of the affected common carotid artery increased from 1.5 ± 0.23 to 3.5 ± 1.4 mm and mean wall thickness became thinner from 2.2 ± 0.27 to 0.84 ± 0.26 mm. She is in good health with no signs of relapse of MDS or arteritis without any immunosuppressive agents more than 4 years since CBT.
Allogeneic HSCT has been performed in patients with AID and hematological disorders.
1-3, 8 Daikeler et al. 8 performed a retrospective analysis of 35 patients receiving allogeneic HSCT for AID, and its response rate and TRM at 2 years were 79% (CR 55% and PR 24%) and 22.1%, respectively. They concluded that allogeneic HSCT can induce remission in patients with refractory AID. Graft-versus-autoimmune effect may be one factor underlying its effectiveness, and stem cell replacement itself may also have some effect in curing AID. 9 Although there is now a substantial reduction in the risk of death related to allogeneic HSCT, the indication of allogeneic HSCT for AID is still controversial because of the high risks of treatment-related comorbidities.
MDS is a heterogeneous group of hematopoietic stem cell disorders characterized by dysplasia and peripheral cytopenia. Several reports suggested that MDS may cause several AID including TA. [4] [5] [6] [7] Mori et al. 10 reported BMT in a 32-year-old man with aortitis and chronic myelomonocytic leukemia. The patient required treatment with PSL and MTX for aortitis before BMT, but became independent of immunosuppressive agents 1.5 years after BMT. However, neither MRI nor CT imaging results were shown for evaluation of aortitis after BMT.
Pre-CBT
Post-CBT Figure 1 . Contrast-enhanced CT (a) and MRI (c) performed before transplantation showed significant left common carotid arterial wall thickening. Contrast-enhanced CT (b) and MRI (d) were performed 2 and 3 years after transplantation, respectively, and both showed significant improvement of left common carotid arterial wall thickening.
Here, we described a 34-year-old woman suffering from MDS coexisting with TA, which was refractory to immunosuppressive therapies, including anti-thymocyte globulin, PSL and CsA. CBT was successfully performed for transfusion-dependent MDS, and TA was also significantly improved ( Figure 1 ). The preparative regimen including high-dose CY could have modified the arterial disease; however, it is speculated that the graft-versus-autoimmune effect of CBT was involved in regression of stenosis because improvement of arteritis was sustained for over 2 years without immunosuppressive agents after CBT. Remission of MDS may have contributed to attenuation of TA, which was potentially associated with MDS as a paraneoplastic phenomenon. The cases of pure primary TA may not respond to allogeneic HSCT in the same way. Alternatively, cord blood as the stem cell source may have had a role in the improvement of arteritis in this case. Some studies have demonstrated that cord blood stem cells have the potential to induce vasculogenesis. 11 There have been reports of CBT for AID, such as Evans syndrome, especially in pediatric settings, 3, 8 but only anecdotal data are available. To our knowledge, this is the first report indicating the effectiveness of CBT for TA. Well-designed prospective clinical trials are needed to establish an appropriate stem cell source, conditioning regimen and GVHD prophylaxis in allogeneic HSCT for refractory AID.
